STERIS plc
For the period ended Mar 31, 2024. Filed May 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed May 29, 2024
STE$256.94+1.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholder's Equity
(in thousands, except per share amounts)
| Ordinary Shares · RetainedEarnings · AccumulatedOtherComprehensiveLoss · Non-controllingInterest · TotalEquity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number · Amount | ||||||||
| Balance at March 31, 2021 | 85,353 | $2,002,825 | $1,939,408 | $(61,243) | $10,478 | $3,891,468 | ||
| Comprehensive income: | ||||||||
| Net income (loss) | — | — | 243,888 | — | (1,018) | 242,870 | ||
| Other comprehensive loss | — | — | — | (148,565) | — | (148,565) | ||
| Repurchases of ordinary shares | (353) | (34,894) | (20,883) | — | — | (55,777) | ||
| Equity compensation programs and other | 770 | 67,499 | — | — | — | 67,499 | ||
| Cash dividends – $1.69 per ordinary share | — | — | (163,169) | — | — | (163,169) | ||
| Issuance of shares for acquisition of Cantel Medical LLC ("Cantel") | 14,297 | 2,689,317 | 2,689,317 | |||||
| Consideration related to equity component of Cantel convertible debt | 175,555 | 175,555 | ||||||
| Consideration related to Cantel equity compensation programs | 18,173 | 18,173 | ||||||
| Reclassification to Cantel convertible debt, premium liability | (175,555) | (175,555) | ||||||
| Distributions to noncontrolling interest holders | — | — | — | — | (997) | (997) | ||
| Contributions from noncontrolling interest holders | — | — | — | — | 3,672 | 3,672 | ||
| Other changes in noncontrolling interest | — | — | — | — | 146 | 146 | ||
| Balance at March 31, 2022 | 100,067 | 4,742,920 | 1,999,244 | (209,808) | 12,281 | 6,544,637 | ||
| Comprehensive income: | ||||||||
| Net income (loss) | — | — | 107,030 | — | (1,217) | 105,813 | ||
| Other comprehensive loss | — | — | — | (110,902) | — | (110,902) | ||
| Repurchases of ordinary shares | (1,642) | (297,322) | (11,243) | — | — | (308,565) | ||
| Equity compensation programs and other | 204 | 40,777 | — | — | — | 40,777 | ||
| Cash dividends – $1.84 per ordinary share | — | — | (183,498) | — | — | (183,498) | ||
| Distributions to noncontrolling interest holders | — | — | — | — | (794) | (794) | ||
| Other changes in noncontrolling interest | — | — | — | — | (296) | (296) | ||
| Balance at March 31, 2023 | 98,629 | $4,486,375 | $1,911,533 | $(320,710) | $9,974 | $6,087,172 | ||
| Comprehensive income: | ||||||||
| Net income | — | — | 378,239 | — | 1,840 | 380,079 | ||
| Other comprehensive loss | — | — | — | (7,947) | — | (7,947) | ||
| Repurchases of ordinary shares | (77) | (10,208) | (1,557) | — | — | (11,765) | ||
| Equity compensation programs and other | 331 | 67,009 | — | — | — | 67,009 | ||
| Cash dividends – $2.03 per ordinary share | — | — | (200,570) | — | — | (200,570) | ||
| Distributions to noncontrolling interest holders | — | — | — | — | (1,562) | (1,562) | ||
| Contributions from noncontrolling interest holders | — | — | — | — | 2,994 | 2,994 | ||
| Other changes in noncontrolling interest | — | — | — | — | (64) | (64) | ||
| Balance at March 31, 2024 | 98,883 | $4,543,176 | $2,087,645 | $(328,657) | $13,182 | $6,315,346 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.